Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Methotrexate
Clonmel Healthcare Ltd
L01BA01
Methotrexate
25 mg/ml
Solution for injection in pre-filled syringe
Subcutaneous or intramuscular injection
0.3 ml, 0.4 ml, 0.6 ml, 0.8 ml, 1.0 ml pre-filled syringe, in packs of 1
Product subject to prescription which may not be renewed (A)
Antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues
Active rheumatoid arthritis in adult patients; polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to non-steroidal antiinflammatory drugs (NSAIDs) has been inadequate; severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis
Authorised
2015-06-26
PACKAGE LEAFLET: INFORMATION FOR THE USER25 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Methotrexate _ _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Soma hati kamiliis and what it is used for 2. What you need to know before you use 3. How to use 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR is a medicine with the following properties: - it interferes with the growth of certain cells in the body that reproduce quickly (anti-tumour agent), - it reduces undesired reactions of the body’s own defence mechanism (immunosuppressant), and - it has anti-inflammatory effects. is used for the treatment of: - active rheumatoid arthritis (RA) in adult patients. - polyarthritic forms (when five or more joints are involved) of severe, active juvenile idiopathic arthritis (JIA) when the response to so-called non-steroidal anti- inflammatory drugs (NSAIDs) has been inadequate - severe forms of psoriasis, which cannot be sufficiently treated with conventional therapy such as phototherapy,
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Methotrexate Clonmel 25mg/ml Solution for Injection in Pre-filled Syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains 25 mg methotrexate. 1 pre-filled syringe of 0.3 ml solution for injection contains 7.5 mg methotrexate. 1 pre-filled syringe of 0.4 ml solution for injection contains 10 mg methotrexate. 1 pre-filled syringe of 0.6 ml solution for injection contains 15 mg methotrexate. 1 pre-filled syringe of 0.8 ml solution for injection contains 20 mg methotrexate. 1 pre-filled syringe of 1.0 ml solution for injection contains 25 mg methotrexate. The medicinal product contains maximum 5.21 mg per ml sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection in pre-filled syringe. The medicinal product is a clear, yellowish solution for injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Active rheumatoid arthritis in adult patients. - Polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to non-steroidal anti- inflammatory drugs (NSAIDs) has been inadequate. - Severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, PUVA, and retinoids, and severe psoriatic arthritis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Methotrexate should only be prescribed by physicians who are familiar with the various characteristics of the medicinal product and its mode of action. The administration should routinely be done by health professionals. If the clinical situation permits the treating physician can, in selected cases, delegate the administration to the patient her/himself. In these cases, detailed Soma hati kamili